A PHASE IB-II STUDY OF HIGH-DOSE POST-TRANSPLANT CYCLOPHOSPHAMIDE BORTEZOMIB ABATACEPT AND SHORT-DURATION TACROLIMUS FOR THE PREVENTION OF GRAFT-VERSUS-HOST DISEASE (GVHD) FOLLOWING HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)
Brief description of study
The purpose of the study is to determine the safety and efficacy of cyclophosphamide, abatacept, and short-duration tacrolimus for GvHD prophylaxis following haploidentical hematopoietic stem cell transplantation for patients with hematological malignancies undergoing allogeneic HSCT from first-degree haploidentical donor. Patients will receive non-myeloablative, reduced-intensity or myeloablative conditioning regimen followed by peripheral blood hematopoietic stem cells.
Clinical Study Identifier: s20-00136
ClinicalTrials.gov Identifier: NCT04503616
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
